Review article: the management of refractory Crohn's disease

被引：18

作者：

Rizzello, F ^{[1
]}

Gionchetti, P ^{[1
]}

Venturi, A ^{[1
]}

Morselli, C ^{[1
]}

Campieri, M ^{[1
]}

机构：

[1] Univ Bologna, Dept Internal Med & Gastroenterol, I-40126 Bologna, Italy

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2002年 / 16卷

关键词：

D O I：

10.1046/j.1365-2036.16.s4.6.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However. this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy.

引用

页码：40 / 47

页数：8

共 50 条

[1] Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis [J].

Baert, FJ ;

D'Haens, GR ;

Peeters, M ;

Hiele, MI ;

Schaible, TF ;

Shealy, D ;

Geboes, K ;

Rutgeerts, PJ .

GASTROENTEROLOGY, 1999, 116 (01) :22-28

[2] TUMOR-NECROSIS-FACTOR-ALPHA IN STOOL AS A MARKER OF INTESTINAL INFLAMMATION [J].

BRAEGGER, CP ;

NICHOLLS, S ;

MURCH, SH ;

STEPHENS, S ;

MACDONALD, TT .

LANCET, 1992, 339 (8785) :89-91

[3] TUMOR-NECROSIS-FACTOR ALPHA-PRODUCING CELLS IN THE INTESTINAL-MUCOSA OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].

BREESE, EJ ;

MICHIE, CA ;

NICHOLLS, SW ;

MURCH, SH ;

WILLIAMS, CB ;

DOMIZIO, P ;

WALKERSMITH, JA ;

MACDONALD, TT .

GASTROENTEROLOGY, 1994, 106 (06) :1455-1466

[4]

Cohen RD, 2000, AM J GASTROENTEROL, V95, P3469

[5] BONE-MARROW TOXICITY CAUSED BY AZATHIOPRINE IN INFLAMMATORY BOWEL-DISEASE - 27 YEARS OF EXPERIENCE [J].

CONNELL, WR ;

KAMM, MA ;

RITCHIE, JK ;

LENNARDJONES, JE .

GUT, 1993, 34 (08) :1081-1085

[6] Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease [J].

Cornillie, F ;

Shealy, D ;

D'Haens, G ;

Geboes, K ;

Van Assche, G ;

Ceuppens, J ;

Wagner, C ;

Schaible, T ;

Plevy, SE ;

Targan, SR ;

Rutgeerts, P .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (04) :463-473

[7] Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy [J].

Cuffari, C ;

Hunt, S ;

Bayless, TM .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (08) :1009-1014

[8] Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial [J].

D'Haens, G ;

Van Deventer, S ;

Van Hogezand, R ;

Chalmers, D ;

Kothe, C ;

Baert, F ;

Braakman, T ;

Schaible, T ;

Geboes, K ;

Rutgeerts, P .

GASTROENTEROLOGY, 1999, 116 (05) :1029-1034

[9] TUMOR-NECROSIS-FACTOR ANTIBODY TREATMENT IN CROHNS-DISEASE [J].

DERKX, B ;

TAMINIAU, J ;

RADEMA, S ;

STRONKHORST, A ;

WORTEL, C ;

TYTGAT, G ;

VANDEVENTER, S .

LANCET, 1993, 342 (8864) :173-174

[10] High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy [J].

Farrell, RJ ;

Murphy, A ;

Long, A ;

Donnelly, S ;

Cherikuri, A ;

O'Toole, D ;

Mahmud, N ;

Keeling, PWN ;

Weir, DG ;

Kelleher, D .

GASTROENTEROLOGY, 2000, 118 (02) :279-288

← 1 2 3 4 5 →